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Abstract
Objective—Improvement in survival of extremely premature infants over the past several
decades has resulted in an increase in the number infants with chronic lung disease (CLD).
Historical neonatal exposures associated with CLD now less frequently precede the disease. There
is now increasing interest in exposures and events before delivery that predict CLD. The objective
of this study was to identify current antenatal predictors of CLD.
Patients and Methods—We collected data about antenatal, placental and neonatal
characteristics of 1241 newborns delivered before completion of the 28th week of gestation who
were enrolled in a 14-center, observational study conducted during the years 2002-2004.
Associations between antenatal factors, microbiologic and histologic characteristics of the
placenta, and selected neonatal characteristics and CLD risk were first evaluated in univariate
analyses. Subsequent multivariate analyses investigated the contribution of antenatal factors,
particularly fetal growth restriction (FGR), to CLD risk.
Results—Among the antenatal factors, birth weight Z-score, used as a marker of FGR, provided
the most information about CLD risk. Indicators of placental inflammation and infection were not
associated with increased risk of CLD. Within nearly all strata of antenatal, placental and neonatal
variables, growth restricted infants were at increased CLD risk compared with infants who were
not growth restricted. FGR was the only maternal or antenatal characteristic that was highly
predictive of CLD after adjustment for other risk factors.
Conclusions—FGR is independently associated with the risk of CLD. Thus factors that control
fetal somatic growth may have a significant impact on vulnerability to lung injury, and in this way
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increase CLD risk. Future investigations should focus on the impact of FGR on growth factors that
modulate lung growth.
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Introduction
Over the past several decades, mortality among extremely low gestational age newborns
(ELGANs) has decreased dramatically.(1,2) However, the improvement in survival has been
offset by an increase in the number of the most vulnerable preterm infants who survive with
bronchopulmonary dysplasia (BPD)(3,4), also called chronic lung disease (CLD). The most
common form of CLD is now less severe, with fewer infants requiring prolonged support
with high levels of supplemental oxygen and mechanical ventilation.(5,6) When first
reported, BPD was attributed primarily to neonatal exposures resulting from treatments for
respiratory distress syndrome (i.e., high levels of supplemental oxygen and mechanical
ventilation).(7) Currently, however, CLD often is preceded by little or no exposure to these
therapies.(8,9) Although immaturity remains the primary determinant of an infant's risk of
developing CLD, increasing attention is now being directed to the identification of
exposures and events before delivery that predict CLD.
In a large, contemporary cohort of ELGANs, we investigated the relationship between
antenatal factors and CLD. In addition to gestational age and birth weight, several antenatal
factors predicted CLD, including fetal growth restriction (FGR). In this paper, we explore
the associations among antenatal and neonatal risk factors to determine if FGR has an
independent effect on CLD risk.
Patients and Methods
The ELGAN Study
The ELGAN Study was designed to identify characteristics and exposures that increase the
risk of structural and functional neurologic disorders among infants born at extreme
prematurity.(10) From 2002-2004, women who delivered before completion of the 28th
week of gestation at 14 institutions were enrolled. The study was approved by the individual
institutional review boards.
Demographic and pregnancy variables
Selected characteristics of the pregnancy and intrapartum period were recorded, including
the clinical circumstances that led to each preterm delivery. These indications for delivery
were operationally defined and mutually exclusive.(11) Two were particularly important in
this study, preeclampsia (PE) and fetal indications (FI). Preeclampsia was defined as new
onset hypertension and proteinuria of sufficient severity to warrant delivery. Fetal
indications (FI) included non-reassuring fetal testing, oligohydramnios, Doppler
abnormalities of umbilical cord blood flow, and severe intrauterine growth restriction based
on clinical ultrasound testing.
Placenta microbiology and morphology
Placental samples were collected for both histologic examination and microbiologic studies.
After removal of the amnion, a specimen of chorion was removed using sterile technique.
This specimen was immediately frozen in liquid nitrogen and then stored in a -80°C freezer.
Eighty-two percent of the samples were obtained within 1 hour of delivery. Frozen samples
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were shipped on a regular basis using dry ice from the 14 study sites to the central
microbiology laboratory. Cultures for selected placental pathogens were performed by
methods described previously.(12,13) After removal of the specimen for microbiologic
assessment, placentas were processed for morphologic assessment as part of the daily
workflow of the clinical departments. Details describing the criteria for each histologic
lesion are presented elsewhere.(14)
Newborn variables
Gestational age estimates were based on a hierarchy of the quality of available information
including, in order of priority, estimates based on the dates of embryo retrieval or
intrauterine insemination or fetal ultrasound before the 14th week (62%), fetal ultrasound at
14 or more weeks (29%), LMP without fetal ultrasound (7%), and gestational age recorded
in the log of the neonatal intensive care unit (1%).
The birth weight was recorded, and the birth weight Z-score (BW Z-score), the number of
standard deviations the infant's birth weight is above or below the median weight of infants
at the same gestational age in a standard data set(15), was calculated for each infant.
Physiologic, laboratory and therapy data from the neonatal medical record were collected
daily for the first week of life and for postnatal days 7, 14, 21, 28. The final details of the
infant's hospital course were collected at discharge, while selected respiratory outcomes
were collected at 36 weeks post-menstrual age (PMA).
Infants were classified by their respiratory characteristics during the first two postnatal
weeks into three mutually exclusive groups: those with consistently low FiO2 (FiO2< 0.23
on all days between 3 and 7 postnatal days and receiving ≤ 0.25 on Day 14), those with
pulmonary deterioration (FiO2 < 0.23 on any days between 3 and 7 days and receiving >
0.25 on day 14), and those with early and persistent pulmonary dysfunction (FiO2
consistently ≥ 0.23 on all days between 3 and 7 postnatal days and receiving > 0.25 on Day
14).(9) Other morbidities were reported if diagnoses were recorded in the hospital chart. The
diagnosis of patent ductus arteriosus (PDA) was made on the basis of clinical signs and
symptoms or by echocardiography. Necrotizing enterocolitis was classified according to the
modified Bell staging system.(16) The diagnosis of CLD was based on whether or not the
child was receiving supplemental oxygen at 36 weeks PMA. Decisions to administer
supplemental oxygen were made by infants' clinical providers and were not based on a
uniform threshold of blood oxygenation prescribed by the study.
Data analysis
The associations of antenatal factors and risk of CLD were first evaluated in univariate
analyses. Subsequent analyses investigated whether FGR modified risk. The relationships
between CLD and characteristics of the placenta, as well as neonatal characteristics, were
examined in a similar manner. Neonatal characteristics were selected on the basis of their
identified association with CLD in previously published studies.
Finally, we created conditional logistic regression models of CLD risk that enabled us to
compare the contribution of PE and FI to the contribution of growth restriction in light of the
potential confounding of gestational age.(17) To account for the possibility that infants born
at a particular hospital are more like each other than like infants born at other hospitals, a
hospital cluster term was included in all models.(18) We used step down procedures seeking
parsimonious solutions without interaction terms. The contributions of relevant variables are
presented as risk ratios with 95% confidence intervals.
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During the study period, mothers of 1506 infants consented to participate. Approximately
260 women were either missed or did not consent. Among the 1506 infants, 1251 survived
to 36 weeks PMA. The CLD status at 36 weeks PMA was not known for 10 infants; the
remaining 1241 infants constitute the population for this study.
In addition to gestational age, birth weight and gender, BW Z-score provided the most
information about CLD risk. Table 1 summarizes risk of CLD in strata defined by antenatal
and delivery characteristics among infants who had any degree of growth restriction
(defined as a BW Z-score < -1) and those who did not (BW Z-score ≥ -1). The data are the
percent of infants in each cell with CLD. For example, 74% of white infants with FGR had
CLD, whereas 50% of white infants without FGR had CLD. Within nearly all strata defined
by antenatal and infant characteristics identifiable at the time of birth, infants with FGR
were at increased risk of CLD (Table 1). Two of six delivery indications (PE and FI) were
associated with higher risk of CLD in the total sample. These indications also included a
high percentage of infants with FGR (66% and 52%, respectively). Multi-fetal gestations
constitute 32% of the sample, but this characteristic did not increase the risk of either FGR
or CLD. In fact, severe growth restriction (BW Z-score < -2) was more common in
singletons (6%) than in twins (4%) and triplets (1%). The incidence of CLD was similar
among singletons (53%) compared to infants of multi-fetal gestations (50%).
The formats for Tables 2-4 are the same as that of Table 1. Although 51% of placental
cultures were positive, culture results provided no additional information about the risk of
CLD (Table 2). However, within each stratum defined by the presence or type of organism,
growth restricted infants were at higher risk of CLD than were their normal weight peers.
Except for the presence of increased syncytial knots, histologic characteristics of the
placenta provided no additional information about CLD risk (Table 3). Neither
chorioamnionitis nor funisitis (umbilical vasculitis) were associated with increased risk.
Within each stratum of histologic characteristics, growth restricted infants were at higher
risk of CLD than were their normal weight peers.
Previously reported associations between CLD risk and high SNAP, late infection, PDA,
NEC and a variety of pulmonary variables were confirmed in our cohort (Table 4). Within
nearly all strata defined by neonatal characteristics, infants with FGR were at higher CLD
risk than were their peers without growth restriction. Even among infants without a postnatal
variable associated with increased CLD risk, those with FGR were at increased risk. Indeed,
this association was generally stronger among infants without postnatal risk factors for CLD.
For example, we observed an association among infants without pulmonary interstitial
emphysema, but not among those with this diagnosis.
Because FGR was associated with PE and FI, as well as with CLD, we evaluated the inter-
relationships among gestational age, indication for delivery, growth restriction and CLD in
greater detail, including after stratifying by degree of FGR (i.e., BW z-score < -2, ≥ -2 to <
-1, and ≥ -1). Table 5a summarizes associations between delivery indication and CLD in
strata defined by gestational age, whereas Tables 5b and 5c summarize associations between
FGR and CLD in strata defined by gestational age (5b) or delivery indication (5c). Fetal
growth restriction was associated with increased risk of CLD at all gestational ages, except
among the least mature infants (23-24 weeks) with severe FGR (Table 5b). Our failure to
detect an association in this stratum may reflect its small size (5 infants). The influence of
FGR appears to be especially high at the oldest gestational ages. At 27 weeks, 25% of
infants without FGR developed CLD compared to 60% of infants with moderate FGR and
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90% of infants with severe FGR. Among infants of preeclamptic mothers, risk of CLD
increased only in the presence of FGR (Table 5c).
We created logistic regression models to evaluate the contribution of FGR to CLD risk in
light of potential confounders (Table 6). We evaluated the contribution of PE and FI (versus
all other indications) while controlling for gestational age in the Z-score < -1 stratum. The
analysis was repeated in the Z-score ≥ -1 stratum. Finally, the third model let the delivery
indication variables compete with the growth restriction variables in the entire sample, again
while controlling for gestational age. Delivery indication variables convey minimal
information in either stratified or total sample models. In contrast, the two groups of growth
restricted infants were at significantly greater risk of CLD than infants who were not growth
restricted (i.e., birth weight Z-score ≥ -1) in the total sample model that included delivery
indication and gestational age.
Discussion
The purpose of our study was to investigate relationships between antenatal factors and CLD
risk. We found that among infants born before the completion of the 28th week of gestation,
the presence of growth restriction during fetal life is prominently associated with an
increased risk of CLD. Because FGR may result from a variety of maternal conditions, most
notably preeclampsia, a critical aspect of our investigation was to explore the inter-
relationships among these conditions and CLD risk. The association between FGR and CLD
risk persists after adjustment for a variety of antenatal and neonatal characteristics also
associated with CLD risk. In fact, FGR was the only maternal or antenatal characteristic that
was highly predictive of CLD after these adjustments.
In contrast to some previous studies, we found no association between markers of placental
or fetal infection and inflammation and CLD risk. Two of these studies report a relationship
between elevated concentrations of the pro-inflammatory cytokine interleukin-6 (IL-6) in
cord blood, and CLD risk.(19,20) One possible explanation for the difference between our
observations and these reports is that we used funisitis, rather than cord blood IL-6, as a
marker of fetal inflammation. However, this explanation is uncertain because funisitis has
been associated with higher cord blood IL-6 levels.(21) An additional study reported an
association between histologic chorioamnionitis, but not funisitis or elevated cord blood
IL-6 levels, and CLD risk.(22) That study enrolled more mature infants compared to our
cohort. It is possible that the antecedents of lung injury may vary with gestational age, with
inflammation more likely to influence risk among infants born after the 27th week of
gestation. Finally, two additional studies identified increased CLD risk following
chorioaminionitis, but only among infants also exposed to prolonged mechanical ventilation
during the early neonatal period.(23,24) These studies used varying techniques for
accounting for the effect of confounders. After extensive adjustment of our data for critical
antenatal confounders, particularly FGR, we conclude that, among infants at the earliest
gestations, intrauterine infection and inflammation does not increase the risk of CLD.
Several large, contemporary studies have previously identified an association between FGR
and CLD risk. In one study of a geographically-defined population in the United Kingdom,
which did not adjust for potential confounders, the risk of CLD was increased among small
for gestational age (SGA) infants and decreased among large for gestational age infants.(25)
A study of infants from a regional population in Germany found that SGA infants were at
increased risk of CLD defined as treatment with oxygen at 28 days of age (26), an endpoint
with less relevance in extremely immature infants. A third study found that infants
considered growth restricted at birth, based on an obstetrical diagnosis of intrauterine growth
restriction or by identifying infants who were SGA, were more likely than their normal
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weight peers to need respiratory support of any kind at 28 days of age.(27) Several other
small studies report associations between restricted fetal growth and CLD risk.(28-30)
Despite methodologic differences between these studies and ours, collectively they support
the strong relationship between impaired fetal growth and CLD risk.
Our findings suggest that processes that limit fetal growth may also limit fetal lung growth
and maturation, thereby making the lung more vulnerable to adversities after birth. Lung
development is highly programmed and regulated by a variety of growth factors and
hormones. For example, a critical phase in lung development is angiogenesis under the
influence of vascular endothelial growth factors and their receptors. Abnormal angiogenesis
appears to be a feature in the pathogenesis of CLD.(31) (32) An imbalance between
angiogeneic and anti-angiogeneic factors also appears to be a critical feature in the
pathogenesis of preeclampsia(33) and among preeclamptic mothers who deliver an infant
with growth restriction.(34) In the presence of preeclampsia, this imbalance might result in a
cascade of events, including disruption of normal placental angiogenesis, a cardinal feature
of preeclampsia, and abnormal fetal angiogenesis, including the vasculature of the fetal lung.
Our observed association between increased syncytial knots in the placenta, a histologic
correlate of preeclampsia(35), and CLD supports this hypothesized scheme of events.
Although we did not observe an increase in CLD risk among infants of preeclamptic
mothers who were not growth restricted, it is possible that abnormal angiogenesis in the fetal
lung occurs only when preeclampsia reaches a sufficient severity to cause FGR.
Fetal growth restriction has also been attributed to the failure of the placenta to meet the
fetus's needs for oxygen and substrate(36), and hypoxia may have secondary effects on the
fetal lung. In neonatal mice, chronic hypoxia during the first two weeks of life, a period of
lung development that corresponds to human fetal lung development during the third
trimester, interferes with alveolar and pulmonary artery development and up-regulates
transforming growth factor beta (TGFβ).(37) Therefore, it is possible that chronic fetal
hypoxia in humans causes both growth restriction and impairment of lung development, the
latter perhaps mediated by TGFβ.
FGR may also cause ineffective or abnormal lung growth after birth as a result of abnormal
programming of growth. This possibility is suggested by two observational studies. In one
study, lung function was measured at approximately 10 months of age in SGA infants and
compared to measurements in appropriately grown premature infants.(38) Increased airway
resistance was associated with FGR after adjustment for confounders, including CLD. This
observation suggests that FGR may impact subsequent growth and development of small
airways. Another study confirmed a relationship between FGR and small airway pathology
by identifying an association between FGR and the risk of childhood asthma.(39)
Rather than influencing lung growth and morphology, factors that result in FGR may alter
the biochemical milieu of the immature lung. Growth restricted mice have reduced
expression of mRNA for surfactant proteins.(40) Perhaps significant alterations in the
surfactant system predispose growth restricted infants to pulmonary abnormalities, resulting
either from a direct effect on the role of surfactant in lung mechanics or in its modulating
role in lung inflammation.
One potential limitation of our study might follow from our defining FGR on the basis of the
relationship between an infant's birth weight and a birth weight distribution for each
gestational age in a similar population. This method may misclassify infants who have
genetically determined growth percentiles that are peculiarly high or low. As an alternative,
when accurate measurements of birth length are available, ponderal index can be used as an
indicator of growth restriction, which for some outcomes may be a more discriminating
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predictor compared to BW Z-score.(39) Finally, BW Z-scores can be calculated using
weight distributions derived from sonographically determined estimates of fetal weights in a
healthy obstetrical population.(41) Compared to this approach, the use of BW Z-scores
calculated from birth weight distributions appears to underestimate fetal growth prior to
term and therefore the frequency of impaired fetal growth.(42)
Because of the observational design of our study, we cannot be certain that FGR is critical in
the causal pathway of CLD. It is possible that FGR is merely a surrogate for other
characteristics of the uterine environment that cause the fetal or neonatal lung to grow or
function poorly. However, it seems likely that factors that control fetal somatic growth in
general have a significant impact on lung growth and development, and in this way increase
CLD risk. Therefore, the ability to modify neonatal pulmonary outcomes among ELGANs
may be dependent on a more precise understanding of the modulators of fetal growth in the
context of problems that result in FGR. Future investigation should focus on these factors.
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Table 6
Logistic regression models with odds ratios (95% confidence limits) of the risk of CLD as a function of
delivery indication, gestational age and fetal growth restriction. The first two models, which do not include
birth weight Z-scores, are in sub-samples defined by their birth weight Z-scores. The last model, based on the
entire sample, includes variables for birth weight Z-score. All models include a hospital “cluster” term to
account for center effects.
Models
Variable Z-score < -1 Z-score ≥ -1 Total
Delivery indication*
Preeclampsia 1.6 (0.8, 3.1) 1.2 (0.6, 2.2) 1.4 (0.9, 2.1)
Fetal indication 1.7 (0.6, 4.9) 2.4 (0.99, 5.9) 2.1 (1.04, 4.1)
Gestational age**
23-24 wks 3.7 (1.1, 12) 11 (7.3, 17) 9.9 (6.7, 15)
25-26 wks 1.4 (0.7, 2.7) 3.0 (2.2, 4.2) 2.5 (1.9, 3.4)
Birth weight Z-score***
≥ -2, < -1 3.2 (2.1, 5.0)
<-2 4.4 (2.3, 8.2)
*
The referent group for each delivery indication category is the category of infants delivered for all other indications.
**
The referent group for each gestational age category is the category of infants born at 27 weeks.
***
The referent group for each birth weight Z-score category is the category of infants with Z-scores ≥ -1.
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